Literature DB >> 15363060

Sensory CIDP presenting as cryptogenic sensory polyneuropathy.

Russell L Chin1, Norman Latov, Howard W Sander, Arthur P Hays, Sidney E Croul, Paul Magda, Thomas H Brannagan.   

Abstract

The objective of this study was to report that patients with chronic inflammatory demyelinating polyneuropathy (CIDP) can present with a clinical picture of cryptogenic sensory neuropathy. Patients with distal sensory neuropathy and electrodiagnostic studies that are minimally abnormal or consistent with an axonal pathology are usually diagnosed as having cryptogenic sensory neuropathy if no cause for neuropathy can be found. Some of these patients, however, may have sensory CIDP. We reviewed the records of eight patients with CIDP, diagnosed by sural nerve biopsy, who presented with sensory neuropathy and electrodiagnostic studies that were minimally abnormal or revealed changes consistent with axonal neuropathy. All patients reported distal numbness and paresthesias and, on examination, had predominantly large fiber distal sensory loss and normal muscle strength. In most patients, deep tendon reflexes were reduced or absent. Sural nerve biopsies in all patients were consistent with chronic myelinopathy, with quantitative teased fiber analysis revealing segmental remyelination in 13-40% of the fibers. The four patients who received IVIg therapy had improved sensation and gait. Of the remaining four patients, one is being followed, one had spontaneous remission, one was lost to follow-up, and one, with contraindications to therapy, reported disease progression. Sensory CIDP may present as cryptogenic sensory polyneuropathy with normal or axonal electrophysiologic features. Sural nerve biopsy should be considered in patients with progressive, predominantly large fiber sensory neuropathy of otherwise unknown etiology, as they may have sensory CIDP that responds to therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363060     DOI: 10.1111/j.1085-9489.2004.09302.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  8 in total

1.  The diagnosis of chronic inflammatory demyelinating polyneuropathy: a Delphi-method approach.

Authors:  Alain Créange; Arnold Careyron
Journal:  J Neurol       Date:  2013-09-20       Impact factor: 4.849

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

Review 3.  Cryptogenic sensory polyneuropathy.

Authors:  Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-03-13       Impact factor: 3.806

Review 4.  Prospects for the Personalized Multimodal Therapy Approach to Pain Management via Action on NO and NOS.

Authors:  Natalia A Shnayder; Marina M Petrova; Tatiana E Popova; Tatiana K Davidova; Olga P Bobrova; Vera V Trefilova; Polina S Goncharova; Olga V Balberova; Kirill V Petrov; Oksana A Gavrilyuk; Irina A Soloveva; German V Medvedev; Regina F Nasyrova
Journal:  Molecules       Date:  2021-04-22       Impact factor: 4.411

5.  Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Eduardo Adonias De Sousa; Thomas H Brannagan
Journal:  Curr Treat Options Neurol       Date:  2006-03       Impact factor: 3.972

6.  Pure sensory chronic inflammatory polyneuropathy: rapid deterioration after steroid treatment.

Authors:  Elisabeth Chroni; Dimitra Veltsista; Evangelia Gavanozi; Tavitha Vlachou; Panagiotis Polychronopoulos; Panagiotis Papathanasopoulos
Journal:  BMC Neurol       Date:  2015-03-11       Impact factor: 2.474

Review 7.  Treatment Approaches for Atypical CIDP.

Authors:  Deepak Menon; Hans Dieter Katzberg; Vera Bril
Journal:  Front Neurol       Date:  2021-03-15       Impact factor: 4.003

8.  The comparison of MRN, electrophysiology and progression among typical CIDP and atypical CIDP subtypes.

Authors:  Yuan Feng; Yu Zhang; Xiaoyun Su; Chuansheng Zheng; Zuneng Lu
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.